Urothelial Cancer

Ali R. Khaki, MD, describes the impact of the EV-103 study of enfortumab vedotin in advanced bladder cancer.

UCSF Health’s Vadim S. Koshkin, MD, highlights approaches for sequencing novel therapies into treatment algorithms for patients with relapsed/refractory advanced bladder cancer.

Dr Benjamin Miron highlights data specific to treating patients with relapsed metastatic disease.

Bradley McGregor, MD, reacts to treatment advances for advanced bladder cancer and shares perspective on utilizing newer, novel therapies as the field continues to evolve

Clinical pearls of advice regarding the optimal management of metastatic urothelial carcinoma in today’s treatment landscape.

Expert perspectives on novel treatment approaches being investigated in the second-line setting of metastatic urothelial carcinoma and beyond.

Practical advice on maintenance therapy in metastatic urothelial carcinoma, covering patient education, duration of therapy, and clinical guidelines.

A review of the JAVELIN Bladder 100 trial, which evaluated avelumab maintenance therapy following frontline chemotherapy in metastatic urothelial carcinoma.

The overall impact that maintenance therapy has had on patient outcomes in advanced or metastatic urothelial carcinoma.

Expert perspectives on optimal treatment approaches in patients with newly diagnosed metastatic urothelial carcinoma.

A brief overview of the advanced urothelial carcinoma landscape encompassing disease course and standard of care treatment strategies.

Manojkumar Bupathi, MD, MS, discusses the evolving treatment landscape of bladder cancer.

Petros Grivas, MD, PhD, discusses the utility of enfortumab vedotin-ejfv in the second- and third-line setting for patients with urothelial carcinoma.

The combination of CG0070 and pembrolizumab was well tolerated and demonstrated early signals of activity in patients with Bacille Calmette-Guérin-unresponsive non–muscle invasive bladder cancer.

Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.

Phillip L. Palmbos, MD, PhD, discusses remaining questions in metastatic urothelial carcinoma.

Matthew Galsky, MD, discusses key developments in the standard-of-care treatment of patients with metastatic or advanced urothelial cancer.

Evan Y. Yu, MD, discusses the utility of enfortumab vedotin-ejfv in patients with locally advanced or metastatic urothelial cancer. 

Petros Grivas, MD, PhD, discusses attempts to improve upon chemotherapy as a therapeutic strategy in urothelial cancer.

Intravesical Bacillus Calmette–Guérin in combination with N-803 resulted in a 12-month disease-free survival rate of 57% in patients with BCG-unresponsive high-grade papillary non–muscle invasive bladder cancer, meeting the primary end point for cohort B of the phase 2/3 QUILT 3.032 trial.

Non-surgical primary chemoablation using mitomycin-containing reverse thermal gel UGN-102 produced significant, durable responses in those with low-grade intermediate-risk non–muscle invasive bladder cancer.

Evan Y. Yu, MD, provided insight into treatment sequencing for patients with metastatic urothelial carcinoma, considerations for treatment decisions, and emerging therapies in the paradigm. 

Jonathan A. Chatzkel, MD, discusses the emergence of novel therapies in relapsed/refractory locally advanced or metastatic urothelial cancer.

Two indications have been granted by the FDA to the Nectin-4directed antibody, enfortumab vedotin-ejfv, marking a shift in the treatment landscape for patients with advanced urothelial carcinoma.

The National Institute for Clinical Excellence has issued final guidance supporting the use of atezolizumab for patients with treatment-naïve, PD–L1–positive locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin.

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

Treatment with the mitomycin-containing reverse thermal gel UGN-101 resulted in a lengthy period of durable response when administered as induction treatment in patients with low-grade upper tract urothelial carcinoma.

The addition of a recombinant pox-viral vector vaccine Panvac™ to bacillus Calmette-Guérin did not significantly improve clinical outcomes for patients with BCG-unresponsive non–muscle invasive bladder cancer.